Superior technology, targets, target binders and modular constructs for cell therapy
Our unique approach to tumor cell targeted killing has the potential to create breakthrough therapies to treat most cancer patients by identifying targets that unequivocally distinguish tumor from normal cells. We do this in two ways: by addressing targets either lost or gained in cancer cells.
A2 leverages a powerful platform that enables identification of rare binders derived from antibodies or TCRs, precision binder engineering and optimization, and modular design. We have potent binders (antibody and TCR fragments that bind to the target) with exquisite selectivity, and modular constructs under development that integrate multiple signals and potentially provide a large therapeutic window.
Our platform technologies under development include:
Assays that quantify T cell proliferation, cytotoxicity and survival either acutely or over time
A high-throughput selection system that enables us to enrich based on binding or function, giving us the flexibility to optimize the most important parameters of cell therapy
Modular constructs that integrate multiple signals to potentially provide a large therapeutic window
Two major types of signal integration: 1) molecular integrator with a single bispecific molecule; and 2) cellular integrator with two independent modules
A component of the platform, the HuTARGTM technology, is licensed from Innovative Targeting Solutions (Vancouver, British Columbia).
Pipeline focused on solid tumor targets
In addition to discovery research, we are planning to innovate in manufacturing. Our autologous cell manufacturing facility will be operational in 2021 with technology scalable for commercial launch.
We aspire to increase speed to patients and reduce cost of goods by advancing the technology and leveraging our cell therapy manufacturing expertise.